Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep;148(9):995-1000.
doi: 10.1001/archdermatol.2012.1401.

Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis

Rahat S Azfar  1 , Nicole M Seminara, Daniel B Shin, Andrea B Troxel, David J Margolis, Joel M Gelfand
Affiliations

Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis

Rahat S Azfar et al. Arch Dermatol. 2012 Sep.

Abstract

Objective: To assess the risk of incident diabetes mellitus (DM) in patients with psoriasis and to evaluate DM treatment patterns among patients with psoriasis and incident DM.

Design: Population-based cohort study.

Setting: United Kingdom-based electronic medical records.

Patients: We matched 108 132 patients with psoriasis aged 18 to 90 years with 430 716 unexposed patients based on practice and time of visit. For our nested study, only patients who developed incident DM during our study time were included.

Main outcome measures: Incident DM and adjusted risk of pharmacotherapy among those with incident DM.

Results: The fully adjusted hazard ratios (95% CIs) for incident DM were 1.14 (95% CI, 1.10-1.18), 1.11 (95% CI, 1.07-1.15), and 1.46 (95% CI, 1.30-1.65) in the overall, mild, and severe psoriasis groups, respectively. Among those with incident DM and severe psoriasis, the adjusted risk for receiving DM pharmacotherapy was 1.55 (95% CI, 1.15-2.10).

Conclusions: Our results suggest that psoriasis is an independent risk factor for the development of type 2 DM in a dose-dependent manner, and that patients with severe psoriasis who develop DM are more likely to receive systemic diabetic therapies in comparison with patients with DM but without psoriasis.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Dr Gelfand has received grants from Amgen, Pfizer, Novartis, and Abbott, and is a consultant for Amgen, Abbott, Pfizer, Novartis, Celgene, and Centocor. Dr Margolis is on the data safety monitoring boards for Abbott, Astellas, and Centocor. No other authors have conflicts of interest to declare.

References

    1. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003–2004. J Am Acad Dermatol. 2009;60:218–224. - PMC - PubMed
    1. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996;14:485–496. - PubMed
    1. Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136–139. - PubMed
    1. Gelfand JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141:1537–1541. - PubMed
    1. Gelfand JM, Wang X, Qing L, Neimann AL, Weinstein R, Margolis DJ. Epidemiology and Treatment Patterns of Psoriasis in the General Practice Research Database (GPRD) Pharmacoepidemiol Drug Saf. 2005;14:23.

Publication types